The two “wings” of Ikaros in B-ALL suppression. (Right) In B-ALL cells, CK2 activity is increased and results in Ikaros phosphorylation that prevents its binding to DNA and regulation of cell cycle and PI3K pathway genes. (Left) On treatment with the specific CK2 inhibitor CX-4945, Ikaros is no longer phosphorylated and can actively repress its target genes, leading to leukemia inhibition.